专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20100298367A1 Conformationally Constrained Carboxylic Acid Derivatives Useful for Treating Metabolic Disorders 有权
标题翻译：用于治疗代谢紊乱的构象约束羧酸衍生物
公开(公告)号：US20100298367A1
公开(公告)日：2010-11-25
申请号：US12863578
申请日：2009-03-04
申请人： Sean P. Brown , Paul J. Dransfield , Jonathan Houze , Todd J. Kohn , Jiwen Liu , Julio Medina , Vatee Pattaropong , Wang Shen , Marc Vimolratana , Yingcai Wang , Ming Yu , Liusheng Zhu
发明人： Sean P. Brown , Paul J. Dransfield , Jonathan Houze , Todd J. Kohn , Jiwen Liu , Julio Medina , Vatee Pattaropong , Wang Shen , Marc Vimolratana , Yingcai Wang , Ming Yu , Liusheng Zhu
IPC分类号： A61K31/216 , A61K31/44 , A61K31/192 , C07D213/63 , C07D213/55 , C07C69/007 , C07C59/62 , A61P9/12 , A61P3/10 , A61P35/04 , A61P13/12 , A61P3/00 , A61P3/06 , A61P9/10 , A61P9/00
CPC分类号： C07C59/72
摘要： The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I or the general formula III: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
摘要翻译：本发明提供了可用于例如治疗受试者的代谢紊乱的化合物。这些化合物具有通式I或通式III：其中本文提供变量的定义。本发明还提供了组合物，其包括化合物在制备药物和用于治疗代谢性疾病例如II型糖尿病中的使用方法。

2. 发明申请

US20090130717A1 Novel K04-0144 Substance and a Process for Production Thereof 有权
标题翻译：新型K04-0144物质及其生产工艺
公开(公告)号：US20090130717A1
公开(公告)日：2009-05-21
申请号：US12084878
申请日：2006-05-16
申请人： Satoshi Omura , Hiroshi Tomoda , Yong-pil Kim , Hideaki Hanaki , Atsuko Matsumoto , Yoko Takahashi
发明人： Satoshi Omura , Hiroshi Tomoda , Yong-pil Kim , Hideaki Hanaki , Atsuko Matsumoto , Yoko Takahashi
IPC分类号： C12P19/44 , C07H15/10 , C12P13/02 , C12N1/20 , C07C59/62
CPC分类号： C07H11/04 , C07C323/59 , C12P13/02 , C12P19/26 , C12P19/44 , C12R1/465
摘要： A microorganism represented by a strain K04-0144 belonging to Streptomyces sp. having ability to produce K04-0144 substance is cultured in the medium, and the isolated K04-0144A substance, K04-0144B substance and K04-0144C substance therefrom have strong antibacterial activities against Gram-positive bacteria including methicillin-resistant Streptococcus aureus (MRSA), consequently these are useful as the therapeutic agents for infectious disease caused by MRSA as well as infectious diseases caused by multidrug including β-lactam antibiotics resistant bacteria. Further, similarly, since the novel K04-0144D substance isolated from the cultured liquid has the action for enhancing the effect of β-lactam antibiotics, which are utilized as the antibacterial agents, in combination with them, it is useful as the therapeutic agent for infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) and multidrug including β-lactam antibiotics resistant bacteria.
摘要翻译：属于Streptomyces sp。的菌株K04-0144所代表的微生物在培养基中培养生产K04-0144物质的能力，分离的K04-0144A物质，K04-0144B物质和K04-0144C物质对革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌（MRSA））具有很强的抗菌活性，因此，这些可用作由MRSA引起的感染性疾病的治疗剂以及由多种药物（包括β-内酰胺抗生素抗性细菌）引起的感染性疾病。此外，类似地，由于从培养液体中分离的新型K04-0144D物质具有增强作为抗菌剂的β-内酰胺抗生素与其组合的作用，因此可用作治疗剂由耐甲氧西林金黄色葡萄球菌（MRSA）引起的感染性疾病和包括β-内酰胺抗生素抗性细菌在内的多种药物。

3. 发明授权

US5840724A Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- o r 失效
公开(公告)号：US5840724A
公开(公告)日：1998-11-24
申请号：US881888
申请日：1997-06-24
申请人： Garry Fenton , Andrew David Morley , Malcolm Norman Palfreyman , Andrew James Ratcliffe , Brian William Sharp , Keith Alfred James Stuttle , Sukanthini Thurairatnam , Bernard Yvon Jack Vacher
发明人： Garry Fenton , Andrew David Morley , Malcolm Norman Palfreyman , Andrew James Ratcliffe , Brian William Sharp , Keith Alfred James Stuttle , Sukanthini Thurairatnam , Bernard Yvon Jack Vacher
IPC分类号： C07C43/225 , C07C45/00 , C07C45/29 , C07C45/71 , C07C47/575 , C07C49/84 , C07C59/58 , C07C59/60 , C07C59/62 , C07C65/21 , C07C65/24 , C07C65/26 , C07C65/42 , C07C69/76 , C07C69/92 , C07C205/59 , C07C217/88 , C07C235/56 , C07C255/60 , C07C275/34 , C07C311/29 , C07C311/46 , C07C317/40 , C07C323/42 , C07C327/48 , C07D213/50 , C07D213/75 , C07D213/89 , C07D239/42 , C07D241/20 , C07D261/14 , C07D275/02 , C07D275/03 , C07D409/12 , C07D213/02 , A61K31/44
CPC分类号： C07C43/225 , C07C205/59 , C07C217/88 , C07C235/56 , C07C255/60 , C07C275/34 , C07C311/29 , C07C311/46 , C07C317/40 , C07C323/42 , C07C327/48 , C07C45/004 , C07C45/292 , C07C45/71 , C07C47/575 , C07C49/84 , C07C59/58 , C07C59/60 , C07C59/62 , C07C65/21 , C07C65/24 , C07C65/26 , C07C65/42 , C07C69/76 , C07C69/92 , C07D213/50 , C07D213/75 , C07D213/89 , C07D239/42 , C07D241/20 , C07D261/14 , C07D275/03 , C07D409/12 , C07C2101/08 , C07C2101/14 , C07C2102/42
摘要： This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.

4. 发明授权

US5068422A Carboxy ethers 失效
标题翻译：羧基醚
公开(公告)号：US5068422A
公开(公告)日：1991-11-26
申请号：US450090
申请日：1989-12-13
申请人： Dieter Balzer , Heinz Reimer , Werner Friedrich
发明人： Dieter Balzer , Heinz Reimer , Werner Friedrich
IPC分类号： B01F17/00 , B01F17/44 , C07C59/125 , C07C59/60 , C07C59/62 , C08G65/26 , C08G65/32 , C08G65/337 , C10M173/00 , C11D1/06
CPC分类号： B01F17/0028 , C07C59/125 , C07C59/60 , C07C59/62 , C08G65/26 , C08G65/337 , C10M173/00 , C11D1/06 , C10M2201/02 , C10M2209/104 , C10M2209/107 , C10N2240/06 , C10N2240/08 , C10N2250/02
摘要： A carboxy ether of formula (II):[R--O(C.sub.3 H.sub.6 O).sub.x (C.sub.2 H.sub.4 O).sub.y (C.sub.3 H.sub.6 O).sub.z ].sub.2 CHCOOM (II)is disclosed. In formula (II) R is (i) a saturated or unsaturated, linear or branched group containing 6 to 20 carbon atoms, (ii) an alkylaromatic group or an alkylcycloaliphatic group, each containing a total of 4 to 16 carbon atoms in its alkyl group, (iii) a dialkylaromatic dialkylcycloaliphatic, or trialkylcycloaliphatic group, each containing a total of 5 to 24 carbon atoms in it alkyl groups, or (iv) a trialkylaromatic group with a total of 7 to 28 carbon atoms in its alkyl groups; x is 0 to 15, y is 1 to 40, z is 0 to 15; and M is an alkali-earth metal cation, an alkaline earth metal cation, an ammonium cation, an alkylammonium cation, or a proton.
摘要翻译：公开了式（II）的羧基醚：[R-O（C 3 H 6 O）x（C 2 H 4 O）y（C 3 H 6 O）z] 2 CHCOOM（II）。在式（II）中，R是（i）含有6至20个碳原子的饱和或不饱和的直链或支链基团，（ii）烷基芳族基团或烷基环脂族基团，其烷基中含有总共4至16个碳原子基团，（iii）二烷基芳族二烷基环脂族基或三烷基环脂族基团，其烷基中含有总共5至24个碳原子，或（iv）其烷基中总共具有7至28个碳原子的三烷基芳族基团; x为0〜15，y为1〜40，z为0〜15; M是碱土金属阳离子，碱土金属阳离子，铵阳离子，烷基铵阳离子或质子。

5. 发明授权

US5006539A Prostaglandins 失效
标题翻译：前列腺素
公开(公告)号：US5006539A
公开(公告)日：1991-04-09
申请号：US319052
申请日：1989-03-06
申请人： Robert L. Jones , Norman H. Wilson
发明人： Robert L. Jones , Norman H. Wilson
IPC分类号： C07C59/74 , A61K31/16 , A61K31/17 , A61K31/195 , A61K31/215 , A61K31/557 , A61P7/02 , A61P11/08 , A61P29/00 , C07C43/315 , C07C45/44 , C07C51/00 , C07C59/325 , C07C59/353 , C07C59/62 , C07C59/80 , C07C59/86 , C07C67/00 , C07C69/608 , C07C69/716 , C07C69/738 , C07C229/28 , C07C229/32 , C07C231/00 , C07C233/05 , C07C233/65 , C07C235/06 , C07C235/20 , C07C235/46 , C07C237/24 , C07C239/00 , C07C275/26 , C07C275/28 , C07C335/16 , C07C401/00 , C07C405/00 , C07D213/55 , C07D277/62 , C07D307/00 , C07D493/00 , C07D493/08
CPC分类号： C07D493/08 , C07C255/00 , C07C405/0041 , C07C405/0091 , C07C43/315 , C07C45/44 , C07C59/62
摘要： Novel compounds have a formula (I) ##STR1## wherein ##STR2## represents a bicyclo [2,2,1] hept-2Z-ene, bicyclo [2,2,1]heptane, 7-oxa-bicyclo [2,2,1] hept-2Z-ene, 7-oxa-bicyclo [2,2,1] heptane, bicyclo [2,2,2] oct-2Z-ene or bicyclo [2,2,2] octane substituted at the 5-position by the group R.sup.1 and at the 6-position by the group ANR.sup.2 R, a 6,6-dimethyl-bicyclo [3,1,1] heptane substituted at the 2-position by the group R.sup.1 and at the 3-position by the group ANR.sup.2 R or at the 2-position by the group ANR.sup.2 R and at the 3-position by the group R.sup.1, a cyclohex-1-ene or cyclohexane substituted at the 4-position by the group R.sup.1 and at the 5-position by the group ANR.sup.2 R or a 1-hydroxyclopentane substituted at the 2-position by the group R.sup.1 and at the 2-position by the group ANR.sup.2 R, R.sup.1 is a 6-carboxyhex-2-enyl group or a modification thereof as defined herein; A is an unbranched or branched aliphatic hydrocarbon group with a chain length between the points of attachment to the divalent cyclic group and to the group NR.sup.2 R of 1 to 5 carbon atoms or such a group substituted by an aromatic group; R.sup.2 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted by an aromatic group or groups; and R is a group --CO.NR.sup.3 R.sup.4, --CS.NR.sup.3 R.sup.4, --CNH.NR.sup.3 R.sup.4, --CO.R.sup.4 or --CO.R.sup.4 in which R.sup.3 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted by an aromatic group or groups, and R.sup.4 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly by an aromatic group or groups and/or through an oxygen or sulphur atom either by an aromatic group or by an aliphatic hydrocarbon group substituted directly by an aromatic group or groups. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.

6. 发明授权

US4628061A Prostaglandins 失效
公开(公告)号：US4628061A
公开(公告)日：1986-12-09
申请号：US531899
申请日：1983-08-23
申请人： Robert L. Jones , Norman H. Wilson
发明人： Robert L. Jones , Norman H. Wilson
IPC分类号： C07C59/74 , A61K31/16 , A61K31/17 , A61K31/195 , A61K31/215 , A61K31/557 , A61P7/02 , A61P11/08 , A61P29/00 , C07C43/315 , C07C45/44 , C07C51/00 , C07C59/325 , C07C59/353 , C07C59/62 , C07C59/80 , C07C59/86 , C07C67/00 , C07C69/608 , C07C69/716 , C07C69/738 , C07C229/28 , C07C229/32 , C07C231/00 , C07C233/05 , C07C233/65 , C07C235/06 , C07C235/20 , C07C235/46 , C07C237/24 , C07C239/00 , C07C275/26 , C07C275/28 , C07C335/16 , C07C401/00 , C07C405/00 , C07D213/55 , C07D277/62 , C07D307/00 , C07D493/00 , C07D493/08 , A61K31/34 , C07C177/00
CPC分类号： C07D493/08 , C07C255/00 , C07C405/0041 , C07C405/0091 , C07C43/315 , C07C45/44 , C07C59/62
摘要： Novel compounds have a formula (I) ##STR1## wherein ##STR2## represents a bicyclo [2,2,1] hept-2Z-ene, bicyclo [2,2,1] heptane, 7-oxa-bicyclo [2,2,1] hept-2Z-ene, 7-oxa-bicyclo [2,2,1] heptane, bicyclo [2,2,2] oct-2Z-ene or bicyclo [2,2,2] octane substituted at the 5-position by the group R.sup.1 and at the 6-position by the group ANR.sup.2 R, a 6,6-dimethyl-bicyclo [3,1,1] heptane substituted at the 2-position by the group R.sup.1 and at the 3-position by the group ANR.sup.2 R or at the 2-position by the group ANR.sup.2 R and at the 3-position by the group R.sup.1, a cyclohex-1-ene or cyclohexane substituted at the 4-position by the group R.sup.1 and at the 5-position by the group ANR.sup.2 R or a 1-hydroxycyclopentane substituted at the 2-position by the group R.sup.1 and at the 2-position by the group ANR.sup.2 R, R.sup.1 is a 6-carboxyhex-2-enyl group or a modification thereof as defined herein; A is an unbranched or branched aliphatic hydrocarbon group with a chain length between the points of attachment to the divalent cyclic group and to the group NR.sup.2 R of 1 to 5 carbon atoms or such a group substituted by an aromatic group; R.sup.2 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted by an aromatic group or groups; and R is a group --CO.NR.sup.3 R.sup.4, --CS.NR.sup.3 R.sup.4, --CNH.NR.sup.3 R.sup.4, --CO.R.sup.4 or --CS.R.sup.4 in which R.sup.3 is hydrogen, an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted by an aromatic group or groups, and R.sup.4 is an aliphatic hydrocarbon group, an aromatic group or an aliphatic hydrocarbon group substituted directly by an aromatic group or groups and/or through an oxygen or sulphur atom either by an aromatic group or by an aliphatic hydrocarbon group substituted directly by an aromatic group or groups. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.

7. 发明授权

US4493846A Bicyclooctane derivatives 失效
标题翻译：双环辛烷衍生物
公开(公告)号：US4493846A
公开(公告)日：1985-01-15
申请号：US243570
申请日：1981-03-13
申请人： Keiichi Ono , Akihiko Sugie , Hajime Kawakami , Shunsuke Sami , Atsuyuki Kojima , Junki Katsube
发明人： Keiichi Ono , Akihiko Sugie , Hajime Kawakami , Shunsuke Sami , Atsuyuki Kojima , Junki Katsube
IPC分类号： C07C69/708 , A61K31/557 , C07C29/09 , C07C29/128 , C07C35/32 , C07C43/196 , C07C47/198 , C07C47/277 , C07C51/00 , C07C51/08 , C07C59/125 , C07C59/13 , C07C59/31 , C07C59/46 , C07C59/62 , C07C67/00 , C07C67/08 , C07C69/734 , C07C405/00 , C07D211/32 , C07D295/08 , C07D295/18 , C07C69/608 , C07C61/13 , C07C61/28 , C07C69/616
CPC分类号： C07C255/00 , C07C29/095 , C07C29/1285 , C07C35/32 , C07C405/0083 , C07C43/196 , C07D211/32 , C07B2200/07 , C07B2200/09 , C07C2102/24 , Y10S514/925
摘要： A compound of the formula ##STR1## wherein X.sup.1 is a free or esterified carboxyl group, a hydroxymethyl group, a cyano group, a group of the formula: ##STR2## (R.sup.a and R.sup.b are each independently a hydrogen atom, a C.sub.1 -C.sub.4 alkyl group, a C.sub.3 -C.sub.7 cycloalkyl group, a benzyl group, a phenyl group, a phenyl group substituted with a halogen atom or a C.sub.1 -C.sub.4 alkyl group, or, when taken together with the adjacent nitrogen atom to which they are attached, they represent a 5 to 7-membered saturated heterocyclic group) or a group of the formula: ##STR3## (R.sup.a and R.sup.b are each as defined above), Y is an ethylene group or a vinylene group, R.sup.1 is a hydrogen atom, a hydroxyl group or a protected hydroxyl group, R.sup.2 is a hydrogen atom or R.sub.1 and R.sub.2, when taken together, means a single linkage to form a double bond between the carbon atoms which they are linked, R.sup.3 is a hydroxyl group or a protected hydroxyl group, R.sup.4 is a hydrogen atom or a C.sub.1 -C.sub.4 alkyl group, R.sup.5 is a hydrogen atom, a C.sub.3 -C.sub.8 alkenyl group, a C.sub.3 -C.sub.8 alkynyl group, a C.sub.1 -C.sub.8 alkyl group, a C.sub.3 -C.sub.7 cycloalkyl group or a group of the formula: --(CH.sub.2).sub.n --B (n is 1 or 2 and B is a C.sub.1 -C.sub.4 alkoxyl group, a C.sub.3 -C.sub.7 cycloalkyl group, or a phenyl or phenoxy group optionally substituted with a halogen atom, a C.sub.1 -C.sub.4 alkyl group, a trifluoromethyl group or a C.sub.1 -C.sub.4 alkoxyl group), A is a group of either one of the formulae: ##STR4## (R.sup.6 and R.sup.7 are each independently a hydrogen atom or a C.sub.1 -C.sub.4 alkyl group) and ##STR5## m.sub.1 is 1 or 2 and m.sub.2 is 0, 1 or 2, and the non-toxic pharmaceutically acceptable salts threreof. Said compounds have strong anti-ulcerogenic activity and are useful in treatment of gastraintestinal ulcer.
摘要翻译：下式的化合物其中X1是游离或酯化的羧基，羟甲基，氰基，下式的基团：（R a和R b各自独立地是氢原子，C 1 -C 4 烷基，C3-C7环烷基，苄基，苯基，被卤素原子或C1-C4烷基取代的苯基，或者当与它们所连接的相邻氮原子一起时，它们表示5至7元饱和杂环基）或下式的基团：（R a和R b各自如上所定义），Y是亚乙基或亚乙烯基，R 1是氢原子，羟基或受保护的羟基，R2是氢原子或R1和R2，当它们一起表示在它们连接的碳原子之间形成双键的单键，R3是羟基或被保护的羟基 R4是氢原子或C1-C4烷基，R5是氢原子，C3-C8链烯基，C3-C8烷基正丁基，C 1 -C 8烷基，C 3 -C 7环烷基或下式基团： - （CH 2）n B（n为1或2，B为C 1 -C 4烷氧基，C 3 -C 7环烷基或任选被卤素原子取代的苯基或苯氧基，C 1 -C 4烷基，三氟甲基或C 1 -C 4烷氧基），A是以下基团之一： R 7各自独立地为氢原子或C 1 -C 4烷基），并且M 1为1或2，m 2为0,1或2，以及无毒的药学上可接受的盐。所述化合物具有强的抗溃疡活性，可用于治疗胃肠溃疡。

8. 发明授权

US4438136A Prostaglandins 失效
标题翻译：前列腺素
公开(公告)号：US4438136A
公开(公告)日：1984-03-20
申请号：US419206
申请日：1982-09-17
申请人： Robert L. Jones , Norman H. Wilson
发明人： Robert L. Jones , Norman H. Wilson
IPC分类号： A61K31/19 , A61K31/557 , A61P7/02 , A61P43/00 , C07C41/54 , C07C43/315 , C07C45/44 , C07C59/46 , C07C59/62 , C07C59/74 , C07C59/80 , C07C67/00 , C07C239/00 , C07C241/00 , C07C251/82 , C07C281/08 , C07C405/00 , A61K31/24
CPC分类号： C07C251/72 , C07C405/0091 , C07C41/48 , C07C45/44 , C07C59/46 , C07C59/62 , C07C59/74 , C07C59/80 , C07C2102/42 , Y10S514/826 , Y10S514/889
摘要： Novel bicyclo [2,2,1] heptanes and hept-2-enes are substituted at the 5-position by a 6-carboxyhex-2-enyl group or a modification thereof, and at the 6-position by a grouping --C(R).dbd.N--NHCO--(NH).sub.a --R' in which R is hydrogen, an aliphatic hydrocarbon residue, an aromatic residue or an aliphatic hydrocarbon residue substituted by an aromatic residue, a is 0 or 1 and R' is an aliphatic hydrocarbon residue, an aromatic residue, or an aliphatic hydrocarbon residue substituted directly or through an oxygen or sulphur atom by an aromatic residue. The compounds are of value for use in pharmaceutical compositions particularly in the context of the inhibition of thromboxane activity.
摘要翻译：新的双环[2,2,1]庚烷和庚-2-烯在5-位被6-羧基己-2-烯基或其修饰取代，并且在6位被-C（ R）= N-NHCO-（NH）aR'，其中R是氢，脂族烃残基，芳族残基或被芳族残基取代的脂族烃残基，a是0或1，R'是脂族烃残基芳族残基，或直接或通过芳族残基被氧或硫原子取代的脂族烃残基。这些化合物在药物组合物中是有用的，特别是在抑制血栓素活性的情况下。

9. 发明授权

US4172954A Chemical compounds 失效
公开(公告)号：US4172954A
公开(公告)日：1979-10-30
申请号：US830294
申请日：1977-09-02
申请人： Kent P. Lannert
发明人： Kent P. Lannert
IPC分类号： C07C51/41 , C07C59/305 , C07C59/31 , C07C59/62 , C07C59/68 , C11D3/20 , C07C69/74 , C07C61/38
CPC分类号： C11D3/2089 , C07C51/412 , C07C59/305 , C07C59/31 , C07C59/62 , C07C59/68
摘要： Organic compounds having a substituent represented by the formula ##STR1## wherein M is alkali metal or ammonium are useful complexing agents for metal and/or alkaline earth metal ions.

10. 发明授权

US4044051A 9[2-(1-Al koxy-ethyl)-5,5-dimethyl-cyclopent-1-en-1-yl]-3,7-dimethyl-nona-2,4,6,8-t etraen acid compounds 失效
标题翻译： 9 {8 2-（1-烷氧基 - 乙基）-5,5-二甲基 - 环戊-1-烯-1-基{9,3,7-二甲基 - 壬-2,4,6,8-四烯酸化合物
公开(公告)号：US4044051A
公开(公告)日：1977-08-23
申请号：US596499
申请日：1975-07-16
申请人： Werner Bollag , Norbert Rigassi , Ulrich Schwieter
发明人： Werner Bollag , Norbert Rigassi , Ulrich Schwieter
IPC分类号： C07C59/62 , C07C63/04 , A61K31/19 , C07C53/00 , C07C61/38
CPC分类号： C07C59/62 , C07C63/04 , Y10S514/859 , Y10S514/863
摘要： 9-[2-(1-alkoxy-ethyl)-5,5-dimethyl-cyclopent-1-en-1-yl]-3,7-dimethyl-nona-2,4,6,8-tetraen acid compounds are disclosed which are useful for the topical or systemic treatment of dermatological disorders.
摘要翻译： 9- [2-（1-烷氧基 - 乙基）-5,5-二甲基 - 环戊-1-烯-1-基] -3,7-二甲基 - 正 - 2,4,6,8-四烯酸化合物被公开用于皮肤病学的局部或全身治疗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式